WebLNC Therapeutics is developing gut microbiota directed drugs to target obesity and associated cardiometabolic diseases. All projects encompass fundamental research, preclinical studies and clinical trials. Backed by leading venture capital investors, such as Seventure Partners (with the microbiome dedicated vehicle Health for Life Capital) and WebMaaT Pharma 7.027 urmăritori pe LinkedIn. We restore microbiome function to treat life-threatening diseases MaaT Pharma has established the most complete approach to …
Log in - maat
Web11 aug. 2024 · Published: Aug 11, 2024 By Tristan Manalac BioSpace French biotech MaaT Pharma announced Wednesday that the U.S. Food and Drug Administration has maintained the clinical hold on MaaT013, its candidate for patients with steroid-resistant acute graft-versus-host disease (aGvHD). Web6 ian. 2024 · Microbiome-based therapeutics hold great promise for reducing disease susceptibility and enhancing disease resistance. In this Review, Sorbara and Pamer explore the major bacterial phyla ... father malek
A Multiple Dose Study to Evaluate Safety, Tolerability, PK, and ...
WebNzingha founded her group private practice, Ma’at Therapeutic Services, with a strong emphasis on “holistic treatment.”. She partners with dynamic practitioners to incorporate various alternative methods of healing into the therapeutic process, including Yoga, Acupuncture, Reiki, Vegan health coaching, massage, and Personal training. Web28 mar. 2024 · Lyon, France, March, 28, 2024 6:00 pm CET – MaaT Pharma (EURONEXT: MAAT – the “Company”), a French clinical-stage biotech and a pioneer in the development of microbiome-based ecosystem therapies dedicated to improving survival outcomes for patients with cancer, announced today that the first patient has been dosed in its pivotal … Web28 mar. 2024 · By restoring the gut microbiome ecosystem, MaaT013 opens a brand-new therapeutic modality and provides a strongly differentiated, immuno-restorative … father malebranche